Mumtaz Score for 30-Day Readmission in Cirrhosis
Predicts 30-day hospital readmission in cirrhotic patients following discharge. Identifies high-risk patients who may benefit from closer follow-up.
Score interpretation
Low 30-day readmission risk (<15%)
→ Standard discharge planning; hepatology outpatient follow-up
Intermediate 30-day readmission risk (15–30%)
→ Early outpatient review within 1–2 weeks; optimise diuretics; patient education
High 30-day readmission risk (>30%)
→ Consider extended stay or early clinic review within 7 days; phone follow-up; social work referral
Interpretation bands for the Mumtaz Score. Apply clinical judgement and local guidance.
References
- Mumtaz K et al. Risk stratification of readmission in patients hospitalized for cirrhosis. J Clin Gastroenterol. 2019;53(9):e385–e390.
Related
Curated clinical cross-links plus same-class fallbacks.
- Spironolactone (Ascites / Cirrhosis) · Aldosterone Antagonist / Potassium-Sparing Diuretic
- Furosemide (Ascites / Cirrhosis) · Loop Diuretic
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.